{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:07:39Z","timestamp":1761487659866,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":2921,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1111\/j.1469-0691.2006.01546.x","type":"journal-article","created":{"date-parts":[[2006,8,7]],"date-time":"2006-08-07T11:09:30Z","timestamp":1154948970000},"page":"1151-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Role of anti-tumour necrosis factor-\u03b1 therapeutic agents in the emergence of infections"],"prefix":"10.1016","volume":"12","author":[{"given":"M.P.","family":"Moiton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Richez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mehsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dehais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2006.01546.x_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2036.1999.00027.x","article-title":"Review article: safety of infliximab in clinical trials","volume":"13","author":"Hanauer","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti\u2010tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti\u2010tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib6","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active\u2010surveillance report","volume":"48","author":"Gomez\u2010Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"9 (suppl)","key":"10.1111\/j.1469-0691.2006.01546.x_bib7","first-page":"S78","article-title":"Infection reports with etanercept (Enbrel) therapy","volume":"44","author":"Wallis","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha\u2010neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib9","first-page":"9","article-title":"Mycobacterium tuberculosis infection in a corticosteroid\u2010treated rheumatic disease patient population","volume":"16","author":"Kim","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2006.01546.x_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.2004.029272","article-title":"Update consensus statement on biological agents, specifically tumor necrosis factor alpha (TNFalpha) blocking agents and interleukin\u20101 receptor antagonist (IL\u20101ra) for the treatment of rheumatic diseases","volume":"63","author":"Furst","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1469-0691.2006.01546.x_bib11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14628652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14628652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:16:34Z","timestamp":1761117394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14628652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S1198743X14628652"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01546.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of anti-tumour necrosis factor-\u03b1 therapeutic agents in the emergence of infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01546.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}